Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.

Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.

Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.

Scholar Rock announced it closed on a Series C financing worth $47 million, with the round led by new investor Invus.

Alexion Pharmaceuticals Inc. announced that the MHLW in Japan approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis.

The U.S. Food and Drug Administration expanded the approval for Alexion Pharmaceuticals Inc.’s blood-disorder drug and blockbuster medicine Soliris.

Alexion Pharmaceuticals Inc. announced results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive.

Catalyst Pharmaceuticals Inc.’s experimental drug to treat patients with a severe form of myasthenia gravis, a rare neuromuscular disease, met the main goals of a study.

Horizon Pharma ended a late-stage trial that was testing Actimmune as a treatment for a rare neuromuscular disorder that has no approved medicines.